ALFA Finder| Margins | EBITDA margin impacted by product mix and lower animal nutrition realizations. |
|---|---|
| Demand visibility | Strong domestic demand; India reached 47% of revenue. |
| Management confidence | High on structural direction and human nutrition growth. |
Growth
Revenue down 13% YoY; PAT down 56% YoY due to exceptionally strong FY26 base with non-recurring income.
Outlook
Investing INR 110 crore in Dahej for Calcifediol; targeting plant-source D3 leadership and expanding into EU/USA markets.
Risks
Animal nutrition volumes fell 52% QoQ/20% YoY; realization down 40% YoY on weak global pricing.
Investor Presentation filed with BSE, NSE: FERMENTA. Summary written with AI assistance from the document.
Fermenta Biotech Ltd: key numbers
- Share price
- ₹452.35
- Market cap
- ₹1,331 Cr
- Revenue (annual)
- ₹525.4 Cr
- Net profit (annual)
- ₹71.77 Cr
- P/E (TTM)
- 25.9×Sector 43.8×
- Promoter holding
- 60.12%-3.97% QoQ
- FII holding
- 1.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fermenta Biotech Ltd
All →Fermenta Biotech Results Update
Fermenta Biotech reported H1FY27 consolidated revenue of Rs. 261.9 Crore, a 7% YoY decline. Profit after tax fell 52% to Rs. 18.9 Crore, impacted by lower animal nutrition pricing.
- Value
- ₹261.9 Cr
Fermenta Biotech Merger & Restructuring
Fermenta Biotech Limited's board has approved the closure of its inactive wholly-owned subsidiary, Fermenta Biotech (UK) Limited. The move aims to reorganize corporate structure and reduce compliance costs following the UK's exit from the EU.
Fermenta Biotech Q2 FY27 Results: Net Profit ₹9.4 Cr, Down 47.8% YoY
Fermenta Biotech Ltd reported revenue from operations of ₹132.7 Cr (+1.9% YoY) and net profit of ₹9.4 Cr (-47.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹9.4 Cr · -47.8% YoY
Fermenta Biotech Board Meeting Date
Fermenta Biotech schedules a board meeting on November 5, 2026 to approve unaudited quarterly and half-year results. The trading window stays closed until 48 hours after results.
Fermenta Biotech Other Announcement
Fermenta Biotech Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Fermenta Biotech Promoter Selling
Fermenta Biotech Limited promoter Preeti Thakkar sold 11,65,938 equity shares (3.96%) in the open market. Her shareholding decreased from 7.61% to 3.65% following the transaction.